Anti-Human EGFR [Clone 225] - Recombinant <i>in vivo</i> Functional Grade (E360-GRP)

Epidermal growth factor receptor (EGFR, also known as ErbB1 or HER 1) is a glycoprotein that belongs to the receptor tyrosine kinase. It plays a role in activating signaling pathways essential, for cellular proliferation, differentiation, and survival1-3. During embryogenesis organogenesis and throughout adulthood EGFR is involved in processes such as tissue growth, differentiation, maintenance, and repair2. Moreover, EGFR acts as a host factor for viral entry in diseases like hepatitis B4, hepatitis C5, and gastroenteritis6. It has also been found to play a role in SARS-CoV-2 infection7-9. Dysregulation of EGFR due to mutation or altered signaling is associated with diseases like Parkinson’s2, Alzheimer’s1, 2, and amyotrophic lateral sclerosis2. Additionally, it has been implicated in the development of cancers including lung, glioblastoma, brain, breast, colorectal, and ovarian3. The binding of ligands to EGFR in cancer cells has been linked to abnormal cell proliferation, invasion, metastasis, angiogenesis, and reduced apoptosis10. Consequently, EGFR serves as a target for cancer treatments including monoclonal humanized antibodies such as panitumumab and cetuximab along with selective small molecule inhibitors11-13. Human Anti-EGFR antibody, clone 225 is a research-grade biosimilar of the monoclonal antibody drug cetuximab. This chimeric antibody contains components from both humans and mice. 225 has been extensively researched in forms of cancer such, as head and neck cell carcinoma, colorectal cancer, and non-small cell lung cancer. Studies have shown that it can be effective when used alongside chemotherapy or radiation therapy presenting an opportunity to enhance outcomes14-22.